Dianthus Therapeutics, INC /DE/ Schedule 13G passive stakes

Sirenia Capital Management LP and Alex Silverstein have reported beneficial ownership of 3.1% of Dianthus Therapeutics, Inc. common stock, including shares issuable from options.

Wellington Management Group LLP and its affiliates have reported a beneficial ownership stake of 5.9% in Dianthus Therapeutics, Inc. as of June 30, 2026.

T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, reporting beneficial ownership of 12.1% of Dianthus Therapeutics Inc. common stock as of July 31, 2026.

T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, reporting beneficial ownership of 7.1% of Dianthus Therapeutics Inc.'s common stock as of June 30, 2026.

Point72 Asset Management and Steven A. Cohen have reported a 1.2% beneficial ownership stake in Dianthus Therapeutics, Inc. as of March 31, 2026.

Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, reporting beneficial ownership of 5.3% of Dianthus Therapeutics, Inc. common stock.

Wellington Management Group LLP and its affiliates have reported beneficial ownership of 4.8% of Dianthus Therapeutics, Inc. common stock as of March 31, 2026.

Octagon Capital Advisors LP and affiliated entities have reported beneficial ownership of 3.6% of Dianthus Therapeutics, Inc. common stock as of March 31, 2026.

BlackRock, Inc. has reported beneficial ownership of 5.1% of Dianthus Therapeutics Inc.'s common stock as of March 31, 2026.

Octagon Capital Advisors LP and its affiliates, including Ting Jia, have reported a 6.1% beneficial ownership stake in Dianthus Therapeutics, Inc. common stock.

BCLS Fund III Investments, LP has filed an Amendment No. 3 to Schedule 13G, disclosing a beneficial ownership of 3.1% in Dianthus Therapeutics, Inc. as of September 30, 2025.

RA Capital Management and its affiliates reported a 9.5% beneficial ownership stake in Dianthus Therapeutics, Inc., totaling 3,866,733 shares.

Vestal Point Capital and Ryan Wilder have reduced their beneficial ownership in Dianthus Therapeutics, Inc. to 3.0% as of September 30, 2025.

Deep Track Capital and its affiliates have filed an amended Schedule 13G, reporting zero beneficial ownership in Dianthus Therapeutics Inc. as of September 30, 2025.

Wellington Management Group and its affiliates have reported a 6.48% beneficial ownership stake in Dianthus Therapeutics, Inc. common stock.

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 15.0% in Dianthus Therapeutics Inc.'s common stock as of September 30, 2025.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, has disclosed a 5.3% beneficial ownership stake in Dianthus Therapeutics, Inc.

BCLS Fund III Investments, LP, part of Bain Capital Life Sciences, reported a 7.5% beneficial ownership stake in Dianthus Therapeutics, Inc., comprising common stock and pre-funded warrants.

Venrock Healthcare Capital Partners and its affiliates have reduced their beneficial ownership in Dianthus Therapeutics, Inc. to 3.1% as of June 30, 2025.

Point72 Asset Management, along with its affiliates and Steven A. Cohen, reported a 4.5% beneficial ownership stake in Dianthus Therapeutics, Inc.

Vestal Point Capital, LP and Ryan Wilder have disclosed a 9.95% beneficial ownership stake in Dianthus Therapeutics, Inc., holding 3.2 million shares of common stock.

RA Capital Management, L.P. and its affiliates, including Peter Kolchinsky and Rajeev Shah, have reported a continued beneficial ownership of 8.9% in Dianthus Therapeutics, Inc., holding 2,866,733 shares of common stock as of March 31, 2025.

TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu have amended their Schedule 13G filing, reporting a beneficial ownership of 4.7% in Dianthus Therapeutics, Inc., indicating a reduction in their stake.

Vestal Point Capital, LP and its Chief Investment Officer, Ryan Wilder, have disclosed a passive 5.3% beneficial ownership stake in Dianthus Therapeutics, Inc., holding 1,700,069 shares of common stock.

Investment giant FMR LLC and its CEO Abigail P. Johnson have reported a combined passive beneficial ownership of 14.0% in Dianthus Therapeutics Inc., holding 4,482,609 shares of common stock as of March 31, 2025.

BlackRock, Inc. has reported a 5.0% beneficial ownership stake in Dianthus Therapeutics, Inc. common stock, held for ordinary course investment purposes.

Point72 Asset Management, along with its affiliates and founder Steven A. Cohen, has disclosed a passive 5.9% ownership stake in Dianthus Therapeutics, Inc., totaling 1,894,304 shares.

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has disclosed a beneficial ownership of 7.34% in Dianthus Therapeutics Inc., totaling 2,357,702 shares of common stock.

RA Capital Management, L.P. and its affiliates have filed an amended Schedule 13G, disclosing a continued 9.4% passive ownership stake in Dianthus Therapeutics, Inc. as of December 31, 2024.

BCLS Fund III Investments, LP, an affiliate of Bain Capital Life Sciences, has reported a beneficial ownership of 8.8% in Dianthus Therapeutics, Inc., as of December 31, 2024.